Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Circulating interleukin‐6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy

Chang, Chin Hao, Hsiao, Chin Fu, Yeh, Yu Min, Chang, Gee Chen, Tsai, Ying Huang, Chen, Yuh Min, Huang, Ming Shyan, Chen, Hui Ling, Li, Yao Jen, Yang, Pan Chyr, Chen, Chien Jen, Hsiung, Chao A., Su, Wu Chou · 2013 · International Journal of Cancer

Abstract

Lung cancer is the leading cause of cancer death worldwide as well as in Taiwan. Interleukin‐6 (IL‐6) is a multifunctional cytokine and has been implicated in tumor progression. This study recruited 245 patients with advanced (Stage 3B/4) nonsmall cell lung cancer (NSCLC) that had received chemotherapy, to evaluate associations between IL‐6 and lung cancer‐specific survival. Among these subjects, 112 gave blood samples before and 133 after the start of chemotherapy. Plasma IL‐6 was measured using an enzyme linked‐immunosorbent assay. The 33rd and 66th percentiles of IL‐6 concentrations were 2.01 and 25.16 for the 245 patients and were defined as the cutoff points for dividing the patients into low, intermediate and high groups. Kaplan‐Meier and Cox proportional‐hazard models were used to evaluate the relationship between the IL‐6 level and survival time. Results after adjusting for age, sex, smoking history, histologic type and stage of lung cancer revealed a significant relationship. For all patients, the hazard ratio with high IL‐6 levels for lung cancer‐specific survival was 2.10 [95% confidence interval (CI) = 1.49 − 2.96] compared with low IL‐6 levels. The hazard ratio for patients who were recruited before and after the start of chemotherapy was1.25 (95% CI = 0.73 − 2.13) and 3.66 (95% CI = 2.18 − 6.15), respectively. Patients with high circulating IL‐6 also responded poorly to chemotherapy. Therefore, a high level of circulating IL‐6 was associated with an inferior response and survival outcome in NSCLC patients treated with chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.27892

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 189

Metadata

Authors
Chang, C. H., Hsiao, C. F., Yeh, Y. M., Chang, G. C., Tsai, Y. H., Chen, Y. M., Huang, M. S., Chen, H. L., Li, Y. J., Yang, P. C., Chen, C. J., Hsiung, C. A., & Su, W. C.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2012-10-29
Volume
132
Issue
9
Pages
1977-1985
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2045588234
Cited by
189
References
3
FWCI
4.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.